Neoadjuvant combination immunotherapy may improve survival compared with single-agent therapy for patients with head and neck squamous cell carcinoma, according to results of a randomized phase 2 ...

Recurrence-free survival rates were similar, even when patients quit adjuvant immunotherapy early, according to a new report.

Recent studies highlight the potential pathophysiology and presentation of immune checkpoint inhibitor–associated cutaneous ...

Cutaneous immune-related adverse events that develop after immune checkpoint inhibitor therapy become chronic in nearly ...

Biotech giant Bristol-Myers Squibb Company BMY is scheduled to report first-quarter 2025 results on April 24, before market ...

Dr. Petros Grivas discusses the importance of tailoring treatment decisions in bladder cancer based on data from three ...